Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427414 · ClinicalTrials.gov registry record · Phase 1
Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma
A Phase 1 study, sponsored by AIDS Malignancy Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00427414 is a Phase 1 study that was terminated before completion, run by AIDS Malignancy Consortium. The registered enrollment target is 14 participants.
The verdict
NCT00427414, a Phase 1 study, was terminated before completion, sponsored by AIDS Malignancy Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma.
Interventions
- DRUG liposomal daunorubicin citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00427414
The ClinicalTrials.gov registry entry for NCT00427414 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which liposomal daunorubicin citrate is the first listed.
NCT00427414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00427414 about?
NCT00427414 is a clinical study titled "Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma". RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HI...
What is the current status of trial NCT00427414?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2008-09. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00427414?
The interventions under investigation include: liposomal daunorubicin citrate (DRUG).
Who is sponsoring clinical trial NCT00427414?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.